Article
|
Open Access
Featured
-
-
Article
| Open Access
Blinded, randomized trial of sonographer versus AI cardiac function assessment
The impact of artificial intelligence in cardiac function assessment is evaluated by a blinded, randomized non-inferiority trial of artificial intelligence versus sonographer initial assessment of the left ventricular ejection fraction.
- Bryan He
- , Alan C. Kwan
- & David Ouyang
-
Article
| Open Access
A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity
A phase I open-label trial evaluating the immunogencity, reactogenicity and safety of a peptide-based SARS-CoV-2 vaccine candidate to induce SARS-CoV-2-specific T cell responses.
- Jonas S. Heitmann
- , Tatjana Bilich
- & Juliane S. Walz
-
Article |
Two chemoattenuated PfSPZ malaria vaccines induce sterile hepatic immunity
Two malaria vaccines comprising Plasmodium falciparum sporozoites and treatment with either pyrimethamine or chloroquine induced durable protective responses against both the African vaccine strain and a heterologous South American strain of P. falciparum.
- Agnes Mwakingwe-Omari
- , Sara A. Healy
- & Patrick E. Duffy
-
Article |
Evaluating eligibility criteria of oncology trials using real-world data and AI
Trial Pathfinder uses data from electronic health records of patients with cancer to evaluate eligibility criteria and broaden restrictive criteria, which facilitates the design of more-inclusive trials while maintaining safeguards for patient safety.
- Ruishan Liu
- , Shemra Rizzo
- & James Zou
-
Article |
Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults
In a dose-escalation study of the COVID-19 RNA vaccine BNT162b1 in 45 healthy adults, RBD-binding IgG concentrations and SARS-CoV-2 neutralizing titres in sera increased with dose level and after a second vaccine dose.
- Mark J. Mulligan
- , Kirsten E. Lyke
- & Kathrin U. Jansen
-
Article |
The National Lung Matrix Trial of personalized therapy in lung cancer
Current outcomes are reported from the ongoing National Lung Matrix Trial, an umbrella trial for the treatment of non-small-cell lung cancer in which patients are triaged according to their tumour genotype and matched with targeted therapeutic agents.
- Gary Middleton
- , Peter Fletcher
- & Lucinda Billingham
-
Letter |
The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs
Clinical benefit was observed in 34% of a cohort of 215 patients with cancer who received treatment with anticancer drugs outside of their approved label, in the Drug Rediscovery protocol trial.
- D. L. van der Velden
- , L. R. Hoes
- & E. E. Voest
-
Article |
Combination therapy with anti-HIV-1 antibodies maintains viral suppression
Combination therapy with the anti-HIV-1 monoclonal antibodies 3BNC117 and 10-1074 maintains long-term suppression in the absence of antiretroviral therapy in individuals with antibody-sensitive viral reservoirs.
- Pilar Mendoza
- , Henning Gruell
- & Michel C. Nussenzweig
-
Review Article |
Challenges and opportunities in controlling mosquito-borne infections
- Neil M. Ferguson
-
Article |
A randomized trial of normothermic preservation in liver transplantation
Normothermic machine perfusion of the liver improved early graft function, demonstrated by reduced peak serum aspartate transaminase levels and early allograft dysfunction rates, and improved organ utilization and preservation times, although no differences were seen in graft or patient survival.
- David Nasralla
- , Constantin C. Coussios
- & Peter J. Friend
-
Letter |
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
The authors report the first-in-human application of personalized neo-antigen RNA vaccines in patients with melanoma.
- Ugur Sahin
- , Evelyna Derhovanessian
- & Özlem Türeci
-
News |
FDA under pressure to relax drug rules
Industry says antibiotic pipeline is being blocked by overly stringent clinical-trial requirements for new treatments.
- Heidi Ledford
-
Comment |
The worm returns
Joel V. Weinstock explains why several clinical trials are deliberately infecting people with helminths to treat autoimmune diseases.
- Joel V. Weinstock
-
News & Views |
Design by trial
A genetic analysis of viruses infecting participants in an HIV vaccine trial indicates that the vaccine is more protective against viruses that have variations at specific sites in the viral envelope. See Letter p.417
- David V. Glidden
-
News |
Drug firm to share raw trial data
Full disclosure could improve health care and restore trust.
- Declan Butler
-
News |
Vaccine trial reveals chinks in HIV's armour
Analysis identifies target for immune response that could improve AIDS vaccines.
- Ewen Callaway
-
Outlook |
Clinical approval: Trials of an anticancer jab
Two vaccines seem to be so effective in preventing HPV infection that mass vaccination has been introduced for girls. But will long-term studies show falls in cervical cancer?
- Julie Clayton
-
News |
India shakes up rules on clinical trials
But compensation scheme draws fire for raising costs for academic researchers.
- Daniel Cressey
-
News |
Stem-cell pioneer banks on future therapies
Japanese researcher plans cache of induced stem cells to supply clinical trials.
- David Cyranoski
-
News |
Europe proposes revision of clinical-trial rules
Much-maligned directive to be overhauled after years of complaints.
- Daniel Cressey
-
-
Outlook |
Perspective: The right trials
The system for clinical trials must be redesigned if there is to be a decline in breast cancer metastasis, argues Patricia S. Steeg.
- Patricia S. Steeg
-
Editorial |
Misplaced childhood
The US National Institutes of Health should rethink plans to limit a nationwide study of children. It must not miss a rare opportunity to probe the causes of childhood diseases.
-
Article |
Human gut microbiome viewed across age and geography
The human gut microbiome from a large cohort of more than 500 indivduals living on three continents with three distinct cultures is analysed, emphasizing the effect of host age, diet and environment on the composition and functional repertoire of fecal microbiota.
- Tanya Yatsunenko
- , Federico E. Rey
- & Jeffrey I. Gordon
-
News |
FDA says study overestimated non-compliance with data-reporting laws
US drug regulator finds no evident harm caused by sponsors failing to post drug-trial data.
- Meredith Wadman
-
-
Review Article |
Emerging fungal threats to animal, plant and ecosystem health
Pathogenic fungi are increasingly contributing to the global emerging disease burden, threatening biodiversity and imposing increasing costs on ecosystem health, hence steps must be taken to tighten biosecurity worldwide to reduce the rate of fungal disease emergence.
- Matthew C. Fisher
- , Daniel. A. Henk
- & Sarah J. Gurr
-
Comment |
How to track a flu virus
Four experts pinpoint ways to improve monitoring of H5N1 avian influenza in the field.
-
News & Views |
Clinical trials unite mice and humans
Anticancer 'co-clinical' trials, in which mice carrying known mutations are treated in parallel with patients enrolled in a simultaneous clinical study, could help to improve therapeutic outcome. See Letter p.613
- Leisa Johnson
-
Correspondence |
Informed consent: cultural differences
- Gilles Guerrier
- , Didier Sicard
- & Paul T. Brey
-
Editorial |
The darker side of stem cells
An investigation by Nature has found that patients in Texas are receiving unproven stem-cell treatments. The state and the company involved need to ensure that they follow FDA guidelines.
-
Feature |
Biostatistics: Revealing analysis
As the challenges of analysing genomic data evolve, statistical expertise has become more valuable than ever.
- Erika Check Hayden
-
News Feature |
Human experiments: First, do harm
In the 1940s, US doctors deliberately infected thousands of Guatemalans with venereal diseases. The wound is still raw.
- Matthew Walter
-
News |
Informed consent on trial
Lengthy, complicated documents leave many clinical-trial participants in the dark about the risks they face.
- Daniel Cressey
-
News |
Fines expose failings in policing of Indian drug trials
Paltry penalties for doctors involved in unethical clinical trials spark controversial reforms.
- M Sreelata
-
Outlook |
Perspective: The clinical trial barriers
To investigate traditional Asian medicines properly, we need to rethink the way they are tested, say Liang Liu, Elaine Lai-Han Leung and Xiaoying Tian.
- Liang Liu
- , Elaine Lai-Han Leung
- & Xiaoying Tian
-
Outlook |
Overview: Multiple lines of attack
Researchers are developing new weapons to fight a deadly form of blood cancer.
- Duncan Graham-Rowe
-
Outlook |
Food: Picky eaters
Clinical trials are testing how careful exposure could protect people with potentially lethal allergies to everyday fare.
- Rebecca Kessler
-
News |
Stem-cell pioneer bows out
Geron halts first-of-its-kind clinical trial for spinal therapy.
- Monya Baker
-
News |
Targeted treatment tested as potential cancer cure
Trial will deploy genetically targeted therapy early, rather than as last resort.
- Erika Check Hayden
-
News |
Depression drug disappoints
Failure of a promising compound casts a shadow on others.
- Heidi Ledford
-
Q&A |
Turning point: Qin Liu
Biostatistician leaves medical career in China for cancer research in the United States.
- Virginia Gewin
-
News |
Malaria vaccine results face scrutiny
Experts question early release of incomplete trial data.
- Declan Butler
-
News |
A fight for life that united a field
Nobel-prizewinner Ralph Steinman tried to beat his cancer with vaccines based on the dendritic cells he discovered.
- Lauren Gravitz
-
News |
Drug shortage slows clinical trials
US researchers faced with cancer-drug shortfall struggle to keep trials on track.
- Heidi Ledford
-
News Feature |
Translational research: 4 ways to fix the clinical trial
Clinical trials are crumbling under modern economic and scientific pressures. Nature looks at ways they might be saved.
- Heidi Ledford
-
News |
Clues emerge to explain first successful HIV vaccine trial
Immune responses of patients could point way forward for future vaccines.
- Ewen Callaway
-
Editorial |
Who watches the watchmen?
Some commercial firms that oversee the ethics and scrutiny of clinical trials have been found wanting. Human volunteers in research deserve better.
-
News Feature |
Experimental therapies for Parkinson's disease: Why fake it?
How 'sham' brain surgery could be killing off valuable therapies for Parkinson's disease.
- Alla Katsnelson
Clinical trial links oncolytic immunoactivation to survival in glioblastoma